古塞奇尤单抗(Guselkumab) - 药物靶点：IL-23p19_在研适应症：活动性中度克罗恩病，活动性重度克罗恩病，活动性中度溃疡性结肠炎_专利_临床

概要

基本信息

药物类型

单克隆抗体

别名

Guselkumab (Genetical Recombination)、Guselkumab (genetical recombination) (JAN)、Guselkumab (USAN)

+ [8]

靶点

IL-23p19

作用方式

抑制剂

作用机制

IL-23p19抑制剂(白细胞介素-23亚单位p19抑制剂)

治疗领域

免疫系统疾病感染消化系统疾病+ [5]

在研适应症

活动性中度克罗恩病活动性重度克罗恩病活动性中度溃疡性结肠炎+ [24]

非在研适应症

腺瘤性结肠息肉病乳糜泻泛发性脓疱型银屑病+ [5]

原研机构

Janssen Global Services LLC

在研机构

Janssen Pharmaceutica NVJanssen-Cilag International NV

西安杨森制药有限公司

+ [10]

非在研机构-

权益机构

Janssen Pharmaceuticals, Inc.

Celsius Therapeutics, Inc.

MorphoSys AG

+ [3]

最高研发阶段批准上市

首次获批日期

美国 (2017-07-13),

斑块状银屑病

最高研发阶段(中国)批准上市

特殊审评优先审评 (中国)、突破性疗法 (中国)、孤儿药 (日本)、临床急需境外新药 (中国)

登录后查看时间轴

结构/序列

Sequence Code 9493545H

来源: *****

Sequence Code 9493571L

来源: *****

关联

93

项与古塞奇尤单抗相关的临床试验

NCT06916390

/ Not yet recruiting临床4期IIT

Guselkumab Intervention and Diet Evaluation for Pouchitis

Restorative proctocolectomy (RPC) with ileal pouch-anal anastomosis (IPAA) is considered the procedure of choice in patients with ulcerative colitis (UC) refractory to medical therapy or with neoplasia. The most common complication after IPAA is the development of pouchitis. Pouchitis is clinically characterized by variable symptoms including increased stool frequency, altered consistency, bloody stools, abdominal cramping, urgency, and incontinence. Symptomatic pouchitis longer than four weeks is considered chronic pouchitis.
The conventional treatment for acute and chronic pouchitis is antibiotics, such as metronidazole and ciprofloxacin. The disease course of antibiotic responsive pouchitis may evolve into antibiotic dependent (requiring antibiotic maintenance therapy) pouchitis and then antibiotic refractory (no response to antibiotic treatment) pouchitis. Although many patients respond to antibiotic therapy, there is also evidence that suggest that aberrant regulation of the mucosal immune system might play a part in the pathogenesis of pouchitis arising from an abnormal mucosal immune response to a dysbiosis of the pouch microbiota. If individuals fail to respond to antibiotics, anti-tumor necrosis factor (anti-TNF) agents and vedolizumab have been proposed for the treatment of chronic pouchitis.
Guselkumab, an interleukin-23 (IL-23) p19 subunit antagonist monoclonal antibody, is proven to be efficacious in patients with moderately-to-severely active UC. Efficacy of guselkumab in treating UC has been shown in multiple large clinical trials. However, patients with pouchitis were never the targeted population and were even often excluded from the trials.
Pouchitis becomes a chronic problem with a huge impact in the quality of life of these patients. The incidence of pouchitis has been rising in the last decades. This increase might be explained by a change in dietary habits of this population.
This open label single center trial at UZ Leuven aims to evaluate the efficacy and safety of guselkumab in the treatment of chronic antibiotic refractory pouchitis during a 48-week treatment period, with or without a dietary intervention. Twenty subjects with a proctocolectomy and IPAA for UC who have developed chronic or relapsing pouchitis will be enrolled.

开始日期2025-09-30

申办/合作机构-

NCT07138898

/ Not yet recruiting临床2期IIT

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

The purpose of this study is to assess the incidence of rheumatologic flares, changes in pain scores (VAS), changes in functional outcomes (PROMIS), wound complications, surgical site infections, and return trips to the operating room for rheumatology patients following shoulder replacements, comparing those who stop their immunosuppressants preoperatively for the same amount of time as suggested in the literature for hip and knee arthroplasty versus those who hold the medications for a shorter period of time preoperatively.

开始日期2025-09-01

申办/合作机构

NYU Langone Health

NCT07141004

/ Recruiting临床4期

A Phase-IV, Multicenter, Non-Comparative, Open-Label Study Evaluating the Safety and Efficacy of Guselkumab Administered Subcutaneously in the Treatment of Indian Patients With Psoriatic Arthritis

The purpose of this study is to evaluate the safety and how well guselkumab treatment works (efficacy) in participants with psoriatic arthritis (PsA; a chronic, autoimmune form of arthritis that causes joint inflammation) who had inadequate response to standard therapies.

开始日期2025-08-12

申办/合作机构

Johnson & Johnson Pvt Ltd.

100 项与古塞奇尤单抗相关的临床结果

登录后查看更多信息

100 项与古塞奇尤单抗相关的转化医学

登录后查看更多信息

100 项与古塞奇尤单抗相关的专利（医药）

登录后查看更多信息

828

项与古塞奇尤单抗相关的文献（医药）

2025-12-31·JOURNAL OF DERMATOLOGICAL TREATMENT

Switching biologic agent in patients with psoriasis: a systematic review and meta-analysis

Review

作者: Sun, YuanQiang ; Zhao, XiTong ; Li, WenChao ; Liu, Hong ; Zhang, LiHong

BACKGROUND:

Multiple biologics are available for psoriasis treatment, but switching treatments is often necessary at some point. The choice between intraclass or interclass biologic switching has not been extensively investigated.

METHODS:

Two independent authors searched the databases PubMed and EMBASE for studies reporting on biologic switching in psoriasis patients. Our study was performed in line with the Preferred Reporting Items for Systematic Reviews and Meta Analyses (PRISMA) guidelines.

RESULTS:

A total of 19 publications, comprising 679 patients, were included. The intraclass switching group consisted of 519 patients, while the interclass switching group included 139 patients. For intraclass switching, there are respectively 160, 326 and 33 patients switched of TNF-α, IL-17, IL-23. For interclass switching, 11 patients switched from TNF-α to IL-17, 6 from IL-17 to IL-23, 41 from IL-17 to IL-12/23, 29 from IL-17 to TNF-α, 15 from IL-12/23 to IL-17, 8 from IL-12/23 to IL-23. After 12 weeks, the proportion of patients achieving Psoriasis Area and Severity Index (PASI)75 was significantly higher in the intraclass switching group compared to the interclass switching group. However, after 16-52 weeks, the PASI75 proportions were comparable between the groups.

CONCLUSION:

Intraclass switching shows better short-term efficacy than interclass switching. However, in the long term, both switching strategies are effective and safe. This study also shows that adalimumab, ixekizumab, and risankizumab are the preferred agents for intraclass switching, whereas guselkumab serves as the primary agent for interclass transitions.

2025-12-31·JOURNAL OF DERMATOLOGICAL TREATMENT

Interleukin-23p19 inhibitors for the treatment of moderate-to-severe psoriasis: an expert opinion of real-world evidence studies in Europe

Review

作者: Thaçi, D. ; Ständer, S.

Background: Psoriasis is a chronic inflammatory disease affecting about 2% of the global population, with moderate-to-severe forms requiring systemic treatment for successful disease management. By targeting the interleukin (IL)-23p19 subunit of IL-23, the master cytokine of psoriasis pathogenesis, guselkumab, tildrakizumab, and risankizumab offer improved risk-benefit profiles.Objective: While randomized clinical trials (RCTs) provide controlled data, real-world evidence (RWE) offers insights into the performance of these therapies in diverse patient populations, including those with comorbidities or difficult-to-treat areas affected. With RWE on these inhibitors constantly emerging, a comprehensive overview and expert interpretation are essential for providing key insights into psoriasis management in clinical practice.Methods: This review, therefore, examined RWE on the effectiveness and safety of IL-23p19 inhibitors compared to their pivotal RCTs.Results: Despite some gaps between RCT and RWE outcomes, particularly in underrepresented subpopulations, IL-23p19 inhibitors show strong effectiveness and favorable safety across both settings in the short- and especially in the long term, accompanied by an improvement in health-related quality of life and reduction of the main symptoms.Conclusion: Altogether, these factors make these medicines ideal treatment options. Future research should focus on improving patient-reported outcomes, specifically addressing psychological and quality-of-life aspects, to further optimize psoriasis management.

2025-12-01·IMMUNOLOGIC RESEARCH

Residual non-specific and disease-specific inflammatory markers in successfully treated young psoriasis patients: a cross-sectional study

Article

作者: Kraner Šumenjak, Tadeja ; Merzel Šabović, Eva Klara ; Božič Mijovski, Mojca ; Janić, Miodrag

Abstract:

Psoriasis is a chronic, immune-mediated disease. The systemic inflammation triggered by psoriasis contributes significantly to increased cardiovascular risk. While various treatments completely clear the skin, the associated effects on systemic inflammation are not yet clear. We investigated residual systemic inflammation in successfully treated patients. Circulating disease-specific and non-specific inflammatory markers were measured and compared in 80 psoriasis patients (aged 30–45 years) successfully treated with topical therapy, methotrexate, adalimumab, secukinumab or guselkumab, and in 20 healthy controls. Non-specific inflammatory markers (high-sensitivity C-reactive protein (hs-CRP), complete blood count (CBC) parameters, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), mean platelet volume-to-platelet ratio (MPR), and red blood cell distribution width-to-platelet ratio (RPR)) and disease-specific inflammatory markers (interferon-γ (IFN-γ), tumor necrosis factor (TNF), interleukin (IL)-1β, IL-12p70, IL-17, and IL-23) were measured and compared between groups. Disease-specific cytokines (IFN-γ, TNF, IL-1β, IL-12p70, and IL-17, but not IL-23), were significantly elevated in patients compared to controls, while non-specific inflammatory markers showed no differences compared to controls. The residual disease-specific cytokines were similarly elevated in all five treated groups. In addition, they correlated significantly with body mass index (BMI) and waist circumference. Our results suggest that psoriasis patients have elevated residual disease-specific cytokines despite successful treatment, while the non-specific inflammatory markers are similar to those in control subjects. Residual disease-specific inflammatory markers correlated with BMI and waist circumference. A possible beneficial effect of body weight control in psoriasis patients merits further investigation. The study was registered at http://clinicaltrials.gov (identifier: NCT05957120) on July 24, 2023.

566

项与古塞奇尤单抗相关的新闻（医药）

2025-08-29

·EINPresswire

January - March 2021 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)

Addyi (flibanserin) Drug hypersensitivity The "Contraindications", "Warnings and Precautions", "Adverse Reactions", and "Medication Guide" sections of the labeling were updated in September 2021 to include hypersensitivity reactions. Addyi labeling Glucagon-like peptide-1 (GLP-1) analogues Adlyxin (lixisenatide) Bydureon (exenatide) Bydureon BCise (exenatide) Byetta (exenatide) Ozempic (semaglutide) Rybelsus (semaglutide) Saxenda (liraglutide) Soliqua (insulin glargine and lixisenatide) Trulicity (dulaglutide) Victoza (liraglutide) Xultophy (insulin degludec and liraglutide) Drug-induced liver injury The "Adverse Reactions" section of the liraglutide and dulaglutide labeling was updated in June 2022 to include information about elevations of liver enzymes. Example: Trulicity labeling FDA determined that no action is necessary at the time for lixisenatide, exenatide, and semaglutide based on available information. Alcohol-based hand sanitizers Exposure via inhalation FDA determined that no action is necessary at the time based on available information. A FDA Drug Safety Communication was issued on June 16, 2021. Amlodipine and Levamlodipine Products Azor (amlodipine and olmesartan medoxomil ) Caduet (amlodipine besylate and atorvastatin calcium) Conjupri (levamlodipine maleate) Consensi (amlodipine besylate and celecoxib) Exforge (amlodipine and valsartan) Exforge HCT (amlodipine/valsartan and hydrochlorothiazide) Lotrel (amlodipine besylate and benazepril hydrochloride) Katerzia (amlodipine benzoate) Norvasc (amlodipine besylate) Prestalia (amlodipine besylate and perindopril arginine) Tribenzor (amlodipine besylate/olmesartan medoxomil and hydrochlorothiazide) Twynsta (amlodipine and telmisartan) Non-cardiogenic pulmonary edema FDA determined that no action is necessary at the time based on available information. Avonex (interferon beta-1a) Betaseron (interferon beta-1b) Extavia (interferon beta-1b) Plegridy (pegylated interferon beta-1a) Rebif (interferon beta-1a) Injection site abscess FDA is evaluating the need for regulatory action. Bavencio (avelumab) Imfinzi (durvalumab) Keytruda (pembrolizumab) Libtayo (cemiplimab-rwlc) Opdivo (nivolumab) Tecentriq (atezolizumab) Scleroderma FDA determined that no action is necessary at the time based on available information. Bavencio (avelumab) Imfinzi (durvalumab) Keytruda (pembrolizumab) Libtayo (cemiplimab-rwlc) Opdivo (nivolumab) Tecentriq (atezolizumab) Cholangitis sclerosing The "Adverse Reactions" section of the Keytruda (pembrolizumab) labeling was updated in August 2021 to include sclerosing cholangitis. Example: Keytruda labeling FDA determined that no action is necessary at the time for Bavencio (avelumab), Imfinzi (durvalumab), Libtayo (cemiplimab-rwlc), Opdivo (nivolumab), and Tecentriq (atezolizumab) based on available information. Chloroquine Generic products containing chloroquine Phospholipidosis The “Warnings” section of the labeling was updated in May 2022 to include information about phospholipidosis. Eliquis (apixaban) Pradaxa (dabigatran etexilate mesylate) Savaysa (edoxaban tosylate) Xarelto (ribaroxaban) Generic products containing dabigatran etexilate mesylate Generic products containing ribaroxaban Menorrhagia The “Use in Specific Populations” section was updated April 2021 to add language to describe the risk of clinically significant uterine bleeding in females of reproductive potential. Eliquis label Pradaxa label Savaysa label Xarelto label Depakote (divalproex sodium) Depakote ER (divalproex sodium) Stavzor (valproic acid) Generic products containing divalproex sodium Generic products containing valproic acid Tubulointerstitial nephritis The "Adverse Reactions" section of the labeling was updated in November 2021 to include tubulointerstitial nephritis. Example: Depakote labeling Dupixent (dupilumab) Alopecias FDA is evaluating the need for regulatory action. H.P. Acthar Gel (corticotropin) Anaphylactic and anaphylactoid responses The "Warnings and Precautions" and "Adverse Reactions" sections of the labeling were updated in October 2021 to include anaphylaxis. Acthar Gel labeling H.P. Acthar Gel (corticotropin) Cardiac arrhythmias The "Warnings and Precautions" and "Adverse Reactions" sections of the labeling were updated in October 2021 to include atrial fibrillations and palpitations. Acthar Gel labeling Ibrance (palbociclib) Kisqali (ribociclib) Kisqali Femara Co-Pack (letrozole and ribociclib) Verzenio (abemaciclib) Second primary malignancy FDA determined that no action is necessary at the time based on available information. Lynparza (olaparib) Drug-induced liver injury FDA determined that no action is necessary at the time based on available information. Ocrevus (ocrelizumab) Autoimmune colitis The "Warnings and Precautions", "Adverse Reactions", "Patient Counseling Information", and "Medication Guide" sections of the labeling were updated in August 2022 to include colitis. Ocrevus labeling Poteligeo (mogamulizumab-kpkc) Acute kidney injury The "Warnings and Precautions" section of the labeling was updated in March 2022 to include glomerulonephritis. Poteligeo labeling Ravicti (glycerol phenylbutyrate) Product labeling issue regarding stability and instructions for administration The container label, carton label, "Medication Guide", and sections of the Prescribing Information ("Dosage and Administration" and "Patient Counseling Information") were updated in September 2021 to enhance the instructions for administration. Ravicti labeling Spravato (esketamine) Hypertensive crisis FDA determined that no action is necessary at the time based on available information. Tremfya (guselkumab) Device use errors resulting in possible missed or partial doses The Tremfya One Press Instructions for Use (IFU) and carton labeling was updated in June 2023 to mitigate medication errors, such as underdose or no dose delivered. Tremfya labeling Trulance (plecanatide) Drug hypersensitivity The “Adverse Reactions” section of the Trulance labeling was updated April 2021 to include skin itching, hives, and rash. Trulance Label Trulance (plecanatide) Vomiting The “Adverse Reactions” section of the Trulance labeling was updated April 2021 to include vomiting. Trulance Label Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

上市批准

2025-08-29

·BioSpace

J&J Ends Rheumatoid Arthritis Program After Disappointing Mid-Stage Data

iStock, SiyueSteuber Nipocalimab, approved as Imaavy for generalized myasthenia gravis earlier this year, failed to show significantly added benefit when used with an anti-TNFα therapy in patients with rheumatoid arthritis. Johnson & Johnson’s FcRn blocker nipocalimab showed no significant therapeutic benefit in a mid-stage rheumatoid arthritis trial, pushing the pharma to discontinue its development. J&J was testing nipocalimab plus an anti-TNFα therapy in the Phase IIa DAISY trial, enrolling more than 100 patients with moderate to severe and active disease who had already had prior treatment. The company did not provide specific data in its announcement on Thursday, only noting that DAISY “did not show sufficient evidence that the combination therapy provided significant added benefit over anti-TNFα therapy alone.” Nipocalimab is a human IgG1 monoclonal antibody that targets the neonatal Fc receptor, in turn lowering levels of IgG. The biologic won the FDA’s approval in April for the treatment of generalized myasthenia gravis, carrying the brand name Imaavy. Aside from rheumatoid arthritis, J&J is continuing to test nipocalimab in other immunology indications, including Sjogren’s disease and systemic lupus erythematosus. “We remain confident in the nipocalimab product having $5B+ potential,” J&J said in its announcement on Thursday. Even with nipocalimab’s retreat from arthritis, however, J&J continues to chip away at the disease. In July, the pharma filed a supplemental submission to the FDA, seeking to add data to the label of its therapeutic antibody Tremfya, showing that it helps prevent the progression of structural damage in patients with active psoriatic arthritis. Tremfya, which targets IL-23, was approved for this disease in 2020 . Thursday’s mid-stage stumble marks a rare miss for J&J. The pharma also suffered a late-stage flop in March for its kappa opioid receptor blocker aticaprant. Results showed “insufficient efficacy” when it was used as a treatment for patients with major depressive disorder. Otherwise, 2025 has been a good clinical year so far for J&J. The same month as its depression defeat, J&J reported that a combination regimen based on Rybrevant bested AstraZeneca’s Tagrisso in a late-stage trial of non-small cell lung cancer, leading to significantly better overall survival. Also in March 2025, J&J’s experimental IL-23 receptor blocker icotrokinra  outperformed placebo and Bristol Myers Squibb’s Sotyktu in a Phase III plaque psoriasis study. In June, J&J’s CAR T therapy JNJ-4496  achieved a 100% objective response rate in a Phase Ib trial of patients with large B cell lymphoma, with complete response rate reaching 80%.

临床结果上市批准临床3期临床2期临床1期

2025-08-27

·药代动力学

百济大手笔！

昨晚消息，百济神州以首付款8.85亿还是美元的价格将Imdelltra的海外销售的Royalty卖给了Royalty Pharma。 Royalty Pharma 是什么公司？ Royalty Pharma 是一家成立于 1996 年的私募股权投资公司，总部位于纽约，是全球最大的生物制药royalty购买者。2020年在Nasdaq上市。这家伙花钱买的不是global license而是Royalty！ Royalty Pharma 还“投资”过哪些医药资产？ Royalty Pharma 的portfolio非常广泛，涵盖 oncology（肿瘤）、neurology（神经）、endocrinology（内分泌）等领域，已收购数百个royalty，部分主要交易（按时间倒序，聚焦 2024-2025 年近期案例）： • 2025 年 6 月：Revolution Medicines - 20 亿美元，包括12.5 亿美（针对癌症药物）和 7.5 亿美元担保债务。 • 2025 年 2 月：Biogen - 2.5 亿美元，用于 litifilimab（3期临床，用于系统性红斑狼疮）。 • 2025 年 1 月：Morphosys - 卖，但此前通过收购获得 Tremfya 和其他管线的royalty。 • 2025 年：Agios Pharmaceuticals - 9.05 亿美元收购 Servier 的 vorasidenib（脑瘤）royalty • 2024 年 9 月：Ascendis Pharma - 1.5 亿美元l协议。 • 2024 年 6 月：Cytokinetics - 5.75 亿美元交易，用于心血管药物。其portfolio包括 45+ 个批准产品和多个开发阶段资产，总价值数百亿美元。 IMDELLTRA是个啥？ 2019年，百济神州与Amgen达成一项价值高达27亿美元的战略合作协议，聚焦于肿瘤领域的药物开发与商业化。公告三个重点产品没有Imdelltra，Imdelltra只是隐藏在其他共同开发的管线中，是典型的“买花瓶把狗盆搭给我吧” 所以说，凭啥royalty卖9亿，因为娘家姓Amgen！

临床3期并购引进/卖出

100 项与古塞奇尤单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10438	古塞奇尤单抗	L04AC16	DB11834

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
活动性中度克罗恩病	中国	Janssen-Cilag International NV	2025-02-20
活动性重度克罗恩病	中国	Janssen-Cilag International NV	2025-02-20
活动性中度溃疡性结肠炎	美国	Janssen Biotech, Inc.	2024-09-11
活动性重度溃疡性结肠炎	美国	Janssen Biotech, Inc.	2024-09-11
手掌和足底脓疱病	日本	Janssen Pharmaceutical KK	2018-11-21
溃疡性结肠炎	韩国	Janssen Korea Ltd.	2018-04-12
克罗恩病	韩国	Janssen Korea Ltd.	2018-04-12
掌跖角化病	韩国	Janssen Korea Ltd.	2018-04-12
红皮病性银屑病	日本	Janssen Pharmaceutical KK	2018-03-23
银屑病	日本	Janssen Pharmaceutical KK	2018-03-23
脓疱型银屑病	日本	Janssen Pharmaceutical KK	2018-03-23
银屑病关节炎	欧盟	Janssen-Cilag International NV	2017-11-10
银屑病关节炎	冰岛	Janssen-Cilag International NV	2017-11-10
银屑病关节炎	列支敦士登	Janssen-Cilag International NV	2017-11-10
银屑病关节炎	挪威	Janssen-Cilag International NV	2017-11-10
斑块状银屑病	美国	Janssen Biotech, Inc.	2017-07-13

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
幼年特发性关节炎	申请上市	美国	Johnson & Johnson	2024-12-02
小儿克罗恩病	临床3期	美国	Janssen Research & Development LLC	2024-03-13
小儿克罗恩病	临床3期	日本	Janssen Research & Development LLC	2024-03-13
小儿克罗恩病	临床3期	奥地利	Janssen Research & Development LLC	2024-03-13
小儿克罗恩病	临床3期	比利时	Janssen Research & Development LLC	2024-03-13
小儿克罗恩病	临床3期	巴西	Janssen Research & Development LLC	2024-03-13
小儿克罗恩病	临床3期	加拿大	Janssen Research & Development LLC	2024-03-13
小儿克罗恩病	临床3期	法国	Janssen Research & Development LLC	2024-03-13
小儿克罗恩病	临床3期	以色列	Janssen Research & Development LLC	2024-03-13
小儿克罗恩病	临床3期	意大利	Janssen Research & Development LLC	2024-03-13

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03158285 (DISCOVER-2, Pubmed \| Rheumatol Ther)	临床3期	银屑病关节炎	739	Guselkumab Q4W	鬱齋簾蓋網窪觸衊衊壓(糧築餘齋夢膚糧鹽壓範) = 觸鹽願糧願鏇憲艱襯構鹹願窪鬱製蓋糧夢衊憲 (繭膚獵窪蓋鑰獵淵夢簾 ) 更多	积极	2025-07-21
				Guselkumab Q8W	鬱齋簾蓋網窪觸衊衊壓(糧築餘齋夢膚糧鹽壓範) = 製膚艱願齋窪鏇觸製淵鹹願窪鬱製蓋糧夢衊憲 (繭膚獵窪蓋鑰獵淵夢簾 ) 更多
NCT05272150 (VISIBLE trial, Pubmed \| JAMA Dermatol)	临床3期	头皮银屑病	108	Guselkumab 100 mg	壓壓鹹構鬱製鏇糧膚網(選遞餘蓋蓋鏇積鏇積壓) = 鹹蓋襯積範遞積簾廠選鹹艱膚窪網鑰選糧鹽築 (構夢築鑰淵窪淵醖鬱淵 ) 更多	积极	2025-06-25
				Placebo	壓壓鹹構鬱製鏇糧膚網(選遞餘蓋蓋鏇積鏇積壓) = 夢淵餘膚醖蓋糧夢醖夢鹹艱膚窪網鑰選糧鹽築 (構夢築鑰淵窪淵醖鬱淵 ) 更多
NCT05272150 (VISIBLE study, Pubmed \| JAMA Dermatol)	临床3期	银屑病	103	Guselkumab 100 mg	鑰鹽醖醖憲構膚築鏇構(鬱齋糧範簾齋範製鹽構) = Infections were the most common adverse events in the guselkumab (16 [20.8%]) and placebo (3 [11.5%]) groups through week 16, predominantly upper respiratory tract infection and nasopharyngitis 艱壓廠顧積餘襯艱壓襯 (構製顧鏇鏇願壓窪窪獵 )	积极	2025-06-25
				Placebo
NCT04397263 (CTgov)	临床3期	克罗恩病	38	Guselkumab	築鏇構淵糧遞網遞衊衊 = 壓鹽鏇製選鹽鏇衊壓遞鑰範醖淵艱齋蓋觸構願 (醖範齋選鑰鏇鏇願鹽窪, 衊鏇範鑰願構鑰鏇衊憲 ~ 淵積範鬱製膚夢膚窪齋) 更多	-	2025-05-20
NCT04033445 (QUASAR, Company_Website) 人工标引	临床2/3期	溃疡性结肠炎	-	TREMFYA	顧醖齋鹽壓襯鬱憲繭繭(鹹構顧選繭構齋觸製夢) = 觸窪蓋齋築淵壓醖鏇範醖淵顧鏇顧繭網淵構壓 (衊衊蓋構膚鬱範襯鹹築 ) 更多	积极	2025-05-05
NCT05528510 (ASTRO, PRNewswire \| Company_Website) 人工标引	临床3期	活动性中度溃疡性结肠炎 \| 活动性重度溃疡性结肠炎	418	TREMFYA® 100 mg q8w	鹹鏇積夢憲構餘艱鬱選(築選顧壓鏇構蓋糧鹽製) = 觸鏇選廠鑰醖築顧艱積憲顧衊鬱餘鹽築製簾艱 (憲範構築獵遞夢壓積醖 ) 更多	积极	2025-05-05
				TREMFYA® 200 mg q4w	鹹鏇積夢憲構餘艱鬱選(築選顧壓鏇構蓋糧鹽製) = 醖遞襯夢製選鏇選窪膚憲顧衊鬱餘鹽築製簾艱 (憲範構築獵遞夢壓積醖 ) 更多
NCT04882098 (APEX, NEWS) 人工标引	临床3期	银屑病关节炎	-	guselkumab	觸鹹餘製襯廠蓋構襯簾(鏇窪廠築築糧壓襯鬱鹹) = 达到了主要终点鏇鹽鏇襯廠廠醖襯觸鏇 (遞衊壓襯憲鹽繭餘壓積 ) 达到更多	积极	2025-04-07
				Placebo
FDA_CDER 人工标引	N/A	克罗恩病	-	Placebo	遞憲膚壓衊艱積鏇鹹廠(選遞鹹醖壓鹽膚壓鹽構) = 糧壓鏇願觸鹹選齋襯蓋鏇衊鏇構窪糧願鏇窪醖 (糧夢糧廠鬱憲鬱鹹糧獵 ) 更多	积极	2025-03-20
				TREMFYATREMFYA 400 mg Subcutaneous Injection at Weeks 0, 4, and 8	遞憲膚壓衊艱積鏇鹹廠(選遞鹹醖壓鹽膚壓鹽構) = 襯網襯簾構鏇選餘膚獵鏇衊鏇構窪糧願鏇窪醖 (糧夢糧廠鬱憲鬱鹹糧獵 ) 更多
NCT03466411 (FDA_CDER) 人工标引	临床2/3期	克罗恩病	721	Placebo (CD1)	齋遞憲構顧淵鑰夢積襯(襯簾壓衊醖襯顧構繭範) = 衊壓艱窪鬱製壓鹽膚餘繭醖壓糧網鹽網襯顧蓋 (築窪膚鹹範廠糧鏇繭簾 ) 更多	积极	2025-03-20
				TREMFYA 200 mg Intravenous Infusion (CD1)	齋遞憲構顧淵鑰夢積襯(襯簾壓衊醖襯顧構繭範) = 積觸構鬱襯簾獵範鹹簾繭醖壓糧網鹽網襯顧蓋 (築窪膚鹹範廠糧鏇繭簾 ) 更多